Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Megna, Matteo; Cinelli, Eleonora; Gallo, Lucia; Camela, Elisa; Ruggiero, Angelo; Fabbrocini, Gabriella

doi:10.1007/s00403-021-02200-7

Cited by 44 publications

(71 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients in the Italian study had undergone several biologic therapies before risankizumab, without success, which means that they represented difficult-to-treat cases, which could be the reason for a marginally higher reduction in mean PASI score in our study [11]. A similar reduction of PASI score in a real-life setting was described by Megna et al and also by Ruggiero et al, who indirectly compared risankizumab with guselkumab [15,16].…”

Section: Discussionsupporting

confidence: 57%

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Gkalpakiotis

Cetkovská

Arenberger

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the effectiveness and safety of risankizumab and its impact on the quality of life of patients with psoriasis in a realworld setting. Methods: We retrospectively analyzed 154 patients from 18 centers in the Czech Republic who had undergone biologic therapy with risankizumab for moderate-to-severe plaque psoriasis. Baseline characteristics included data on comorbidities, demographics, previous therapies, Dermatology Life Quality Index (DLQI) score, and Psoriasis Area and Severity Index (PASI) score. The proportion of patients achieving a 90% improvement in their PASI score from baseline (PASI 90) and complete resolution (PASI 100) after 16, 28, and 52 weeks was analyzed. Results: A total of 95 men and 59 women with mean body mass index (BMI) of 29.6 were enrolled in our analysis. The mean age of the patients was 48.5 years and the mean time from diagnosis until initiation of risankizumab therapy was 22.5 years. After 16 weeks, 63.8 and 44.7% patients achieved PASI 90 and PASI 100 responses, respectively. Improvement continued with time, and the proportion of patients with PASI 90 and PASI 100 responses increased to 82.4 and 67.6%, respectively, at week 52. A significant reduction was observed over time in the DLQI. Patients achieving PASI 100 response at week 16 had a higher reduction in the DLQI score than those with PASI 90 response (-15.9 vs. -11.8). PASI 90 and PASI 100 responses were independent of the BMI and previous biologic therapy. No new safety issues were identified. Conclusions: In this patient population, risankizumab was effective and safe in a real-world setting, and a high number of patients achieved PASI 90 and PASI 100 responses. A higher reduction in the DLQI was seen in patients withThe members of the BIOREP study group are listed in Acknowledgements.

show abstract

Section: Discussionsupporting

confidence: 57%

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Gkalpakiotis

Cetkovská

Arenberger

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…For risankizumab, phase III studies (UltIMMa‐1 and UltIMMa‐2) included a total of 243 patients aged ≥ 65 years and 24 aged ≥ 75 years, without showing any overall differences compared with younger participants, 18 while a recent pooled analysis of two phase III trials (reSURFACE 1 and reSURFACE 2), which included 92 participants aged ≥ 65 years and 17 aged ≥ 75 years, reported a 3‐year safety profile of tildrakizumab comparable with placebo, in terms of rates of major CVEs and serious infection 21 . Even if data about real‐life‐practice are increasing, particularly for guselkumab and risankizumab, to date, real‐world studies focusing on anti‐IL‐23s in elderly patients are still lacking 15–19 . Our real‐world study showed promising results in terms of both safety and efficacy for all anti‐IL‐23.…”

Section: Discussionmentioning

confidence: 99%

“…Anti‐IL‐23 drugs represent the latest class of biologics approved for the treatment of moderate to severe psoriasis. For guselkumab, risankizumab and tildrakizumab, promising results in terms of safety and efficacy have been shown in both clinical trials and real‐life studies 1,13–21 . However, because these are new therapies that have only recently become available, no real‐life data on elderly patients have been reported to date.…”

Section: Introductionmentioning

confidence: 99%

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice

Ruggiero

Fabbrocini

Cinelli

et al. 2021

Clin Experimental Derm

Self Cite

View full text Add to dashboard Cite

Summary Background Elderly patients (aged ≥ 65 years) represent an increasing proportion of patients with psoriasis and 15% of these have moderate to severe disease. Biologics are being used frequently in this group of patients even though safety and efficacy data are limited. In addition, owing to anti‐interleukin (IL)‐23 therapies being a relatively recent option, no data have been reported about their use in elderly patients with psoriasis. Aim To evaluate and compare the safety and efficacy of guselkumab, risankizumab and tildrakizumab in real‐world practice in elderly patients. Methods This was a single‐centre retrospective study that enrolled patients aged ≥ 65 years with moderate to severe plaque psoriasis, treated with guselkumab, risankizumab or tildrakizumab. The length of the study for each group depended on the drug (44 weeks for risankisumab, 40 weeks for guselkumab and 28 weeks for tildrakizumab, owing to its more recent availability in Italy). Results In total, 34 patients were enrolled (n = 20 on guselkumab; n = 8 on risankizumab; n = 6 on tildrakizumab). At Week 4, 29.4% reached 90% improvement in Psoriasis Area and Severity Index (PASI90) and 8.8% reached 100% improvement in PASI (PASI100); at Week 28, PASI90 and PASI100 was reached by 58.8% and 29.4%, respectively. At the final follow‐up (Week 40 or 44, depending on drug), data were available only for the risankizumab (Week 40) and guselkumab (Week 44) and groups, and showed that 71.4% of patients had reached PASI90 and 53.5% had reached PASI100. Four patients (11.7%) discontinued treatment. No significant differences were found between the three groups. The limitations of the study included its retrospective nature of the study, small sample size, and different numbers of patients and follow‐up duration for the different groups (highest for guselkumab, lowest for tildrakizumab). Conclusion The three anti‐IL‐23 therapies assessed are promising, safe and effective options in elderly patients, and there was no significant difference between them. However, more data are needed to confirm our results and to understand their role in the management of this group of patients.

show abstract

“…The authors also presented a series of cases of scalp, hands and/or feet psoriasis, in which rizankizumab was successfully administered after finding no effects of the therapy with IL-17, IL-12/IL-23 (ustekinumab) or guselkumab [21]. The effectiveness of rizankizumab in these locations was confirmed by the observation in a larger group of patients [22]. The researchers observed only a low effect of etanercept and certolizumab pegol in reducing PSSI and PPPASI [20].…”

Section: Psoriasis Of Special Areasmentioning

confidence: 87%

“…Autorzy przedstawili również serię przypadków łuszczycy skóry owłosionej głowy oraz dłoni i/lub stóp, w których po stwierdzeniu braku efektów inhibitorów IL-17, IL--12/IL-23 (ustekinumab) lub guzelkumabu zastosowano z sukcesem rizankizumab [21]. Skuteczność rizankizumabu w tych lokalizacjach potwierdziła obserwacja w większej grupie chorych [22]. Badacze zaobserwowali jedynie niewielki efekt etanerceptu i certolizumabu pegol w redukcji PSSI i PPPASI [20].…”

Section: łUszczyca Miejsc Szczególnychunclassified

Psoriasis in areas difficult to treat and biological therapy

Lis‐Święty¹,

Frątczak²

2021

View full text Add to dashboard Cite

show abstract

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Cited by 44 publications

References 9 publications

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice

Psoriasis in areas difficult to treat and biological therapy

Contact Info

Product

Resources

About